the fda reversed its prior rejection of regenxbio's gene therapy for mps ii (hunter syndrome) in children, following an earlier reversal on uniqure's huntington's disease therapy. both reversals occurred after trump administration personnel changes at the fda. the pattern — multiple high-stakes rejections overturned in sequence following leadership replacement — is structurally unusual for a regulatory body where scientific review independence is the structural norm. the mechanism behind the reversals has not been publicly documented.